CANF Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 21:59):

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction...

Stats
Dagens volum	2 924.00
Gjennomsnittsvolum	17 735.00
Markedsverdi	11.46M
EPS	$0 ( 2024-04-04 )
Neste inntjeningsdato	( $-0.400 ) 2024-06-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.700
ATR14	$0.0360 (1.72%)

Can-Fite Biopharma Ltd Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Can-Fite Biopharma Ltd Økonomi

Annual	2023
Omsetning:	$743 000
Bruttogevinst:	$728 001 (97.98 %)
EPS:	$-1.790

FY	2023
Omsetning:	$743 000
Bruttogevinst:	$728 001 (97.98 %)
EPS:	$-1.790

FY	2022
Omsetning:	$810 000
Bruttogevinst:	$810 000 (100.00 %)
EPS:	$-3.76

FY	2021
Omsetning:	$853 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.106

Financial Reports:

No articles found.

Can-Fite Biopharma Ltd

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.